AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

CRL · NYSE · Medical - Diagnostics & Research

Charles River Laboratories (CRL)

Provider of research models, nonclinical drug-development services, and manufacturing quality-control testing.

$287.20

vs last close+8.19 (+2.94%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	1,027	1,013	1,012	1,026	1,010	1,003	984	1,032	1,005	994	996	1,004
Cost of revenue	665	649	667	672	661	718	666	675	666	686	717	641
Gross profit	362	364	345	354	349	284	318	357	339	308	279	363
	210	231	219	202	232	452	243	257	205	188	159	243
Selling, general & administrative	176	197	186	170	199	196	178	192	178	188	159	229
Other expenses	34	34	33	32	32	256	65	65	27	0	0	15
Operating income	152	133	126	152	117	−168	75	100	134	120	120	120
	−39	76	−27	−32	−26	−49	−39	−29	−47	−414	−150	−67
Interest income	1	2	2	3	2	2	1	1	1	1	1	1
Interest expense	34	34	35	33	30	28	28	30	25	24	27	30
Other non-operating income	5	−109	−8	−1	−4	21	11	−1	21	391	123	36
Income before tax	113	209	99	120	91	−217	36	71	87	−294	−30	53
Income tax expense	25	20	25	25	21	−3	10	19	32	−18	−15	54
Net income from continuing operations	88	189	74	94	70	−214	26	53	56	−276	−15	−1
Other adjustments	0	0	0	0	0	0	0	0	−2	0	0	−1
Net income	87	187	67	90	69	−216	25	52	54	−277	−15	−1
EPS, basic	$1.70	$3.65	$1.31	$1.75	$1.34	−$4.22	$0.50	$1.06	$1.11	−$5.62	−$0.30	−$0.03
EPS, diluted	$1.69	$3.62	$1.30	$1.74	$1.33	−$4.22	$0.50	$1.06	$1.10	−$5.62	−$0.30	−$0.03
Weighted average shares, basic	51	51	51	52	51	51	51	49	49	49	49	48
Weighted average shares, diluted	52	52	52	52	52	51	51	49	49	49	49	48
EBITDA	225	323	219	239	210	−86	184	221	198	−192	64	151
Depreciation & amortization	79	81	85	86	88	102	120	120	85	78	67	67
EBIT	147	242	134	152	122	−189	64	101	113	−270	−3	84